Other infection: septicaemia Time frame: 2 to 6 weeks · solid organ transplant recipients
It is very uncertain whether extended changes other infection: septicaemia Time frame: 30 days compared with short duration antibiotics (very low certainty).
1 finding from 1 review
Other infection: pneumonia Time frame: 30 days · solid organ transplant recipients
It is very uncertain whether extended changes other infection: pneumonia Time frame: 30 days compared with short duration antibiotics (very low certainty).
1 finding from 1 review
Adverse drug reactions · solid organ transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Surgical site infection · solid organ transplant recipients
It is very uncertain whether extended changes surgical site infections* (all) Time frame: 30 days compared with short duration antibiotics (very low certainty).
1 finding from 1 review
Surgical site infections: kidney transplant recipients Time frame: 30 days · solid organ transplant recipients
It is very uncertain whether extended changes surgical site infections: kidney transplant recipients Time frame:… compared with short duration antibiotics (very low certainty).
1 finding from 1 review
Recurrence of symptomatic UTI in children · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in recurrence of symptomatic UTI in children compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence of symptomatic UTI in children without VUR · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in recurrence of symptomatic UTI in children without VUR compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence of symptomatic UTI in children with VUR · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in recurrence of symptomatic UTI in children with VUR compared with placebo or no treatment (low certainty).
1 finding from 1 review
Recurrence of symptomatic UTI in children, in studies with adequate allocation concealment · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment probably leads to lower recurrence of symptomatic UTI in children, in studies with adequate… compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Repeat positive urine culture · children with previous UTI and most do not have a renal tract abnormality such as VUR
It is very uncertain whether antibiotic treatment changes repeat positive urine culture compared with placebo or no treatment (very low certainty).
1 finding from 1 review
All adverse events · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in all adverse events compared with placebo or no treatment (low certainty).
1 finding from 1 review
Microbial resistance to prophylactic drug · children with previous UTI and most do not have a renal tract abnormality such as VUR
Antibiotic treatment showed no clear difference in microbial resistance to prophylactic drug compared with placebo or no treatment (moderate certainty).
1 finding from 1 review
Outcomes (up to 2 years for primary outcomes) · primary immunosuppression in kidney transplant recipients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
New onset of diabetes · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in new‐onset diabetes mellitus compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).
1 finding from 1 review
Lymphoma/PTLD · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) showed no clear difference in lymphoma/PTLD compared with calcineurin inhibitors (CNI): secondary outcomes (moderate certainty).
1 finding from 1 review
Tremor · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) leads to lower tremor compared with calcineurin inhibitors (CNI): secondary outcomes (high certainty).
1 finding from 1 review
GFR · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Cholesterol mg/dL · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Serum fasting triglyceride (TG, mmol/L) · primary immunosuppression in kidney transplant recipients
1 finding from 1 review
Thrombocytopenia · primary immunosuppression in kidney transplant recipients
Target of rapamycin inhibitors (TOR‐I) may leads to higher thrombocytopenia compared with calcineurin inhibitors (CNI): secondary outcomes (low certainty).
1 finding from 1 review